FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
MONDAY, March 18, 2024 -- The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 18, 2024 Category: Pharmaceuticals Source Type: news

FDA Approves First CAR-T for Chronic Lymphocytic Leukemia
(MedPage Today) -- The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers Squibb announced on Thursday... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news

U.S. FDA Approves Bristol Myers Squibb ’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.--(BUSINESS WIRE) Mar 14, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2024 Category: Drugs & Pharmacology Source Type: news

Popular Acne-Treatment Products Found to Contain High Levels of Carcinogenic Chemical
Hand sanitizers were tainted by benzene. Sunscreens and dry shampoos too. Now acne treatments are joining the list of widely used consumer products found to contain high levels of the chemical linked to cancer. Acne products from brands including Proactiv, Target Corp.’s Up & Up and Clinique have elevated levels of the carcinogen, an independent testing laboratory said in a petition filed with the U.S. Food and Drug Administration late Tuesday. The lab asked the FDA to recall the affected treatments—all of which contain the active ingredient benzoyl peroxide—while regulators investigate. [time-bri...
Source: TIME: Health - March 7, 2024 Category: Consumer Health News Authors: Anna Edney / Bloomberg Tags: Uncategorized News Desk overnight wire Source Type: news

FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Besponsa (inotuzumab ozogamicin) for Pediatric Patients with Acute Lymphoblastic Leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Efficacy was... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 6, 2024 Category: Drugs & Pharmacology Source Type: news

All-Oral AML Regimen Shows Promise for Older, Unfit Patients
(MedPage Today) -- An all-oral combination of decitabine-cedazuridine (Inqovi) plus venetoclax (Venclexta) was active and safe in older or unfit acute myeloid leukemia (AML) patients deemed ineligible for intensive chemotherapy, results of a phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news

Global Cancer/Tumor Profiling Market Research Report 2023-2030: Multi-Omics Tumor Profiling Advances Fuel Developments, Rising Personalized Medicine Trends Driving Growth
DUBLIN, March 1, 2024 /PRNewswire/ -- The "Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO) - Global Forecast to... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 1, 2024 Category: Pharmaceuticals Tags: MRR Source Type: news

Man in remission from blood cancer and HIV after remarkable treatment
Paul Edmonds of California is fifth-known person in world confirmed to be in remission from both, says cancer instituteDoctors say a man inCalifornia who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.Paul Edmonds is only the fifth-known person in the world confirmed to be in remission for both acute myelogenous leukemia and HIV, according to a recentnews release from City of Hope, the national cancer institute that provided his medical care.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 28, 2024 Category: Science Authors: Ramon Antonio Vargas Tags: US news Infectious diseases Medical research Aids and HIV Cancer research California World news Science Source Type: news

New Trials in Leukemia/Lymphoma: Could Your Patient Benefit? New Trials in Leukemia/Lymphoma: Could Your Patient Benefit?
Perhaps one of your patients would benefit from enrolling in a new clinical trial in leukemia or lymphoma?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 28, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

The Unique Hell of Getting Cancer as a Young Adult
When I got diagnosed with Stage 3b Hodgkin Lymphoma at age 32, it was almost impossible to process. Without a family history or lifestyle risk factors that put cancer on my radar, I stared at the emergency room doctor in utter disbelief when he said the CT scan of my swollen lymph node showed what appeared to be cancer—and lots of it. A few days away from a bucket list trip to Japan, I’d only gone to the emergency room because the antibiotics CityMD prescribed to me when I was sick weren’t working.I didn’t want to be sick in a foreign country. So when the doctor told me of my diagnosis, the  on...
Source: TIME: Health - February 23, 2024 Category: Consumer Health News Authors: Maria Yagoda Tags: Uncategorized freelance Source Type: news

Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
WEDNESDAY, Feb. 21, 2024 -- For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue of Leukemia Research. Hannah Goulart,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2024 Category: Pharmaceuticals Source Type: news

Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML
(MedPage Today) -- A 68-year-old man with HIV-1 who underwent hematopoietic cell transplant (HCT) for acute myelogenous leukemia 5 years ago has been free of HIV infection for 35 months after stopping antiretroviral treatment (ART), according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 15, 2024 Category: Hematology Source Type: news

Development of CAR-T Cells for T-ALL Targeting CCR9, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed in the majority of cases of T-ALL but... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2024 Category: Pharmaceuticals Tags: FVT TRI Source Type: news

FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia
(MedPage Today) -- Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and chemotherapy, a preliminary... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 13, 2024 Category: Hematology Source Type: news